ClinicalTrials.gg
Active, not recruitingNCT07133633Updated Nov 12, 2026

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

A Phase 2 interventional study of Tulisokibart and Placebo in Radiographic Axial Spondyloarthritis, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 108 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Planned enrollment
11th of 31
315 · median 200
Started
2025
with 3 others
Phase 2
4 of 34
none open now
Registered
29th of 34
by date

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 11th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 2, and was the 29th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays.

This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart.

Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Read the detailed description

This study consists of a 16-week Placebo-controlled Period and a 124-week Long-term Extension (LTE), which is composed of a 40-week Main Extension and an 84-week Optional Extension.

03

Conditions studied

  • Radiographic Axial Spondyloarthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a clinical diagnosis of axial spondyloarthritis (axSpA) and meets the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA including ≥3 months of back pain with age at symptom onset \<45 years
  • Meets the radiographic criterion of the modified New York criteria for ankylosing spondylitis (AS) as determined by central reading at Screening
  • Has active disease at Screening and Randomization
  • Has a history of inadequate response (IR)/intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) and is biologic disease-modifying antirheumatic drug (bDMARD)-naive, or has a history of IR/intolerance to up to a maximum of 2 bDMARD classes

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than radiographic axial spondyloarthritis (r-axSpA) (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis (PsA), systemic sclerosis, myositis, etc.), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of r-axSpA
  • Has a history of cancer (except fully treated non-melanoma skin cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years
  • Has any active infection
  • Has known allergies, , or intolerance to tulisokibart or its
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    High-dose tulisokibart

    Participants receive a high dose of tulisokibart.

    Drug: Tulisokibart

  • Experimental
    Medium-dose tulisokibart

    Participants receive a medium dose of tulisokibart.

    Drug: Tulisokibart

  • Experimental
    Low-dose tulisokibart

    Participants receive a low dose of tulisokibart and are rerandomized at week 16 to a medium or high dose of tulisokibart.

    Drug: Tulisokibart

  • Placebo comparator
    Placebo

    Participants receive a matched placebo dose and are rerandomized at week 16 to a medium or high dose of tulisokibart.

    Drug: Placebo

Interventions

  • Subcutaneous (SC) administration

    Also known as: MK-7240, PRA023

  • DrugPlacebo

    SC administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Week 16

    ASAS 40 is defined as a relative improvement of ≥40% and an absolute improvement of ≥2 units from baseline in ≥3 of 4 domains, with no deterioration in the fourth domain. The 4 domains include Patient Global Assessment (PtGA), total spinal pain, physical function, and morning stiffness. Each domain is measured on a 10-point numeric scale from 0 = no disease symptoms/impact to 10 = extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) <2.1 at Week 16

    ASDAS is a disease activity measure calculated from the assessments of total spinal pain, duration of morning stiffness, peripheral pain/swelling, PtGA, and high sensitivity C-reactive protein (hsCRP) as follows: 0.121 × total spinal pain (Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 2) + 0.110 × PtGA + 0.073 × peripheral pain/swelling (BASDAI question 3) + 0.058 × duration of morning stiffness (BASDAI question 6) + 0.579 × natural logarithm (ln) of (hsCRP + 1). ASDAS \<2.1 indicates low disease activity and a higher score indicates greater disease activity.

    Time frame: Week 16

  2. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

    The BASFI is a validated 10-item measure assessing individual-reported function (8 items) and ability to cope with everyday life (2 items) over the past week. Responses are recorded for each item on an 11-point numeric rating scale (NRS) from 0 "easy" to 10 "impossible". A mean score of the 10 items will be calculated to reflect the overall functional impairment, with higher scores indicating greater disability.

    Time frame: Baseline and Week 16

  3. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Spine at Week 16

    The SPARCC MRI score for spine is a validated scoring system developed to assess inflammation in the spine related to axSpA. The 6 most abnormal discovertebral units are selected, and 3 consecutive sagittal slices are assessed. Each discovertebral unit is divided into 4 quadrants, scored as 1 if increased signal is present or 0 if normal, with a maximum of 12 points per discovertebral unit. Additional points are added for lesions that exhibit intense signal or deep (≥1 cm), increasing the maximum score per unit to 18. Summed over 6 slices, the maximum total score is 108. Higher scores indicate more extensive and/or intense spinal inflammation.

    Time frame: Baseline and Week 16

  4. Change From Baseline in the SPARCC MRI Score for Sacroiliac Joint (SIJ) at Week 16

    The SPARCC MRI score for SIJ is a validated scoring system to assess SIJ inflammation in axSpA. Six consecutive SIJ coronal slice images are assessed by dividing into 4 quadrants and scored as 1 if increased signal is present or 0 if normal, with a maximum of 8 points per slice for both joints. Additional points are added for lesions that exhibit intense signal or deep (≥1 cm), increasing the maximum score per unit to 12. Summed over 6 slices, the maximum total score is 72. Higher scores indicate more extensive and/or intense SIJ inflammation.

    Time frame: Baseline and Week 16

  5. Change From Baseline in Total Spinal Pain Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 at Week 16

    The BASDAI is a validated 6-item questionnaire used to assess disease activity in radiographic axial spondyloarthritis. It assesses individual-reported fatigue, total spinal pain, peripheral pain/swelling, tenderness, intensity of morning stiffness, and duration of morning stiffness over the past week. To access individual-reported total spinal pain experienced over the past week, participants are asked BADSAI question 2, "How would you describe the overall level of ankylosing spondylitis neck, back, or hip pain you have had?" Responses are recorded on an 11-point NRS ranging from 0 "none" to 10 "very severe." Higher score indicates more severe total spinal pain.

    Time frame: Baseline and Week 16

  6. Change From Baseline in Nocturnal Spinal Pain at Week 16

    The NRS is an 11-point scale (numeric version of the visual analog scale) to assess the pain intensity in individuals who can self-report. Participants will be asked to report their average nighttime spinal pain over the past week on an 11-point NRS. The score range is from 0 "no pain" to 10 "most severe pain." Higher score indicates more severe nocturnal spinal pain.

    Time frame: Baseline and Week 16

  7. Change From Baseline in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) at Week 16

    The ASAS HI assesses overall functioning and health and is a validated 17-item individual-reported measure of pain, emotional functions, sleep, sexual function, mobility, self-care, and community life, with response options of "I agree" (1) or "I do not agree" (0). The ASAS HI is a total summary score ranging from 0 to 17 with a lower score indicating a better and a higher score indicating an inferior health status.

    Time frame: Baseline and Week 16

  8. Change From Baseline in Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) at Week 16

    The SF-36 is a widely used general health status questionnaire that assesses 8 domains of functional health and well-being: physical functioning, role limitations due to physical health problems, bodily pain, social functioning, mental health, role limitations due to emotional problems, vitality, and general health perceptions. The PCS score is a composite score derived from the SF-36 that summarizes the physical health aspects of the survey. It combines information primarily from the physical domains (physical functioning, role limitations due to physical health problems, bodily pain, and general health perceptions). All SF-36 scores range from 0 = worst health state to 100 = best health state, with higher scores indicating a better health-related quality of life (QoL).

    Time frame: Baseline and Week 16

  9. Change From Baseline in BASDAI at Week 16

    The BASDAI is a validated 6-item measure, assessing individual-reported fatigue, total spinal pain, peripheral pain/swelling, tenderness, intensity of morning stiffness, and duration of morning stiffness over the past week. Responses are recorded for each item on an 11-point NRS from 0 "none" to 10 "very severe." BASDAI is calculated by averaging the response for question 5 and question 6, adding this result to the sum of question 1 through question 4, and then dividing the result by 5. A higher score indicates greater disease activity.

    Time frame: Baseline and Week 16

  10. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 16 in the Subgroup of Participants With Enthesitis (MASES>0) at Baseline

    The MASES is a validated method to assess peripheral enthesitis in axSpA. It assesses pain on palpation at the following anatomic sites: first costochondral joint (right \& left); seventh costochondral joint (right \& left); anterior superior iliac spine (right \& left); iliac crest (right \& left); posterior superior iliac spine (right \& left); fifth lumbar spinous process; Achilles tendon, proximal insertion (right \& left). Each site is scored based on participant response as either 0 (nontender) or 1 (tender), the final score ranges from 0 (absence of enthesitis) up to a score of 13 (enthesitis present at all sites). Injected enthesitis sites will be considered not assessable for 90 days from the time of the injection. Higher score indicates more tender or inflamed enthesitis sites. Resolution of enthesitis is defined as MASES score equal to zero.

    Time frame: Baseline and Week 16

  11. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index Linear (BASMI lin) at Week 16

    The BASMI lin is a validated tool to assess mobility in axSpA. The BASMI lin evaluates the range in centimeters of 5 components of hip and spinal mobility (components: tragus-to-wall, lateral lumbar flexion, cervical rotation angle, lumbar flexion, and maximal intermalleolar distance). For tragus to wall, lateral lumber flexion, and cervical rotation angle, the average measurements from left and right would be used as the component score. Component score range is from 0 (no mobility limitation) to 10 (very severe mobility limitation). Higher score indicates more severe mobility limitation.

    Time frame: Baseline and Week 16

  12. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) at Week 16

    The FACIT-Fatigue is a validated 13-item measure that assesses individual-reported fatigue and its impact on daily activities and function during usual activities over the past week. Responses are recorded on a 5-point Likert scale (0 = not at all to 4 = very much), individual item scores are then summed to provide the final score with range from 0 (worst score/extreme fatigue) to 52 (best score/no or minimal fatigue). Higher total scores represent lower levels of fatigue.

    Time frame: Baseline and Week 16

  13. Number of Participants With One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 154 weeks

  14. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 140 weeks

07

Study locations

108 sites

Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Mar 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Sep 26, 2025
Primary completionEst.
Mar 29, 2027was Jun 2027
CompletionEst.
Feb 5, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Sites
4 sites added, 1 site removed. 7 sites changed recruiting status (7 now active, not recruiting)
Show 7 sites
  • MICS Centrum Medyczne Bydgoszcz ( Site 1206) · Bydgoszcz, PolandRecruiting→Active, not recruiting
  • Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council ( Site 1704) · Cherkasy, UkraineRecruiting→Active, not recruiting
  • Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1706) · Kyiv, UkraineRecruiting→Active, not recruiting
  • Municipal Public Non-Profit Enterprise "City Clinical Hospital №1 of the Ivano-Frankivsk City Counc ( Site 1705) · Ivano-Frankivsk, UkraineRecruiting→Active, not recruiting
  • Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 1710) · Lviv, UkraineRecruiting→Active, not recruiting
  • ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 1707) · Ternopil, UkraineRecruiting→Active, not recruiting
  • Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 1700) · Vinnytsa, UkraineRecruiting→Active, not recruiting
Show 4 added (3 United States, 1 Netherlands)
  • Denver Arthritis Clinic ( Site 0064) · Denver, United States
  • The University of Texas Health Science Center at Houston ( Site 0065) · Houston, United States
  • Joseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 0063) · Brooklyn, United States
  • Amsterdam UMC, locatie AMC ( Site 1101) · Amsterdam, Netherlands
Show 1 removed
  • Amsterdam UMC ( Site 1101) · Amsterdam, Netherlands
across 5 updates, Sep 28, 2026 – Nov 12, 2026
Primary completion
Jun 15, 2027→Mar 29, 2027
Nov 12, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • MICS Centrum Medyczne Bydgoszcz ( Site 1206) · Bydgoszcz, PolandContact removed •••1414
  • Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council ( Site 1704) · Cherkasy, UkraineContact removed •••9650
  • Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1706) · Kyiv, UkraineContact removed •••3485
  • Municipal Public Non-Profit Enterprise "City Clinical Hospital №1 of the Ivano-Frankivsk City Counc ( Site 1705) · Ivano-Frankivsk, UkraineContact removed •••3879
  • Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 1710) · Lviv, UkraineContact removed •••8001
  • ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 1707) · Ternopil, UkraineContact removed •••0938
  • Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 1700) · Vinnytsa, UkraineContact removed •••9895
across 3 updates, Sep 28, 2026 – Oct 23, 2026
Show all 5 updates
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Netherlands)
    • Joseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 0063) · Brooklyn, United States
    • Amsterdam UMC, locatie AMC ( Site 1101) · Amsterdam, Netherlands
    Show 1 removed
    • Amsterdam UMC ( Site 1101) · Amsterdam, Netherlands
    Primary completion Jun 15, 2027→Mar 29, 2027
    + 2 other changes: verification date and contact details
  2. Oct 23, 2026
    1 site added. 4 sites changed recruiting status (4 now active, not recruiting)
    Show 4 sites
    • Municipal Public Non-Profit Enterprise "City Clinical Hospital №1 of the Ivano-Frankivsk City Counc ( Site 1705) · Ivano-Frankivsk, UkraineRecruiting→Active, not recruiting
    • Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 1710) · Lviv, UkraineRecruiting→Active, not recruiting
    • ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 1707) · Ternopil, UkraineRecruiting→Active, not recruiting
    • Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 1700) · Vinnytsa, UkraineRecruiting→Active, not recruiting
    Show site
    • The University of Texas Health Science Center at Houston ( Site 0065) · Houston, United States
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Municipal Public Non-Profit Enterprise "City Clinical Hospital №1 of the Ivano-Frankivsk City Counc ( Site 1705) · Ivano-Frankivsk, UkraineContact removed •••3879
    • Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 1710) · Lviv, UkraineContact removed •••8001
    • ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 1707) · Ternopil, UkraineContact removed •••0938
    • Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 1700) · Vinnytsa, UkraineContact removed •••9895
    + 1 other change: references
  3. Oct 20, 2026
    2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council ( Site 1704) · Cherkasy, UkraineRecruiting→Active, not recruiting
    • Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1706) · Kyiv, UkraineRecruiting→Active, not recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council ( Site 1704) · Cherkasy, UkraineContact removed •••9650
    • Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1706) · Kyiv, UkraineContact removed •••3485
  4. Oct 13, 2026
    1 site added
    Show site
    • Denver Arthritis Clinic ( Site 0064) · Denver, United States
    + 1 other change: verification date
  5. Sep 28, 2026
    MICS Centrum Medyczne Bydgoszcz ( Site 1206) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MICS Centrum Medyczne Bydgoszcz ( Site 1206) · Bydgoszcz, PolandContact removed •••1414

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07133633
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Sep 26, 2025
Primary completion
Mar 29, 2027 (estimated)
Completion
Feb 5, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion